FRAZER, Pa., Jan. 25 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq:
CEPH) today announced that the U.S. Food and Drug Administration (FDA) has
accepted the company's supplemental New Drug Application (sNDA) for
FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of
breakthrough pain in opioid-tolerant patients with chronic pain. In
addition, the FDA notified the Company that it will convene an advisory
committee panel on May 6, 2008, to consider this application.
"We are pleased that the FENTORA application remains on schedule with
an FDA action date of September 13, 2008," said Dr. Lesley Russell,
Executive Vice President, Worldwide Medical and Regulatory Operations.
"FENTORA is the first medication that has been evaluated in controlled
clinical trials for the management of breakthrough pain in opioid-tolerant
patients with chronic pain. Therefore, it is not surprising that the agency
decided to convene a panel to consider data on the use of FENTORA beyond
the initial indication for breakthrough pain in cancer patients."
Included in the FENTORA sNDA are data from three randomized, placebo-
controlled clinical trials and one long-term open-label safety study;
including data from opioid-tolerant patients with chronic low back and
neuropathic pain. The sNDA provides an evaluation of the onset of pain
relief from 10 minutes to two hours, and has information regarding
bioequivalence data for two routes of administration.
In 2006, FENTORA and an accompanying Risk Minimization Action Plan
(RiskMAP) were approved by the FDA only for the management of breakthrough
pain in patients with cancer who are already receiving and who are tolerant
to around-the-clock opioid therapy for their underlying persistent cancer
pain. The company developed and maintains a FENTORA RiskMAP to address the
appropriate patient selection, dosing and administration of the medication.
About Cephalon, Inc.
Cephalon, Inc. is an international biopharmaceutical company, recently
inducted into the World Economic Forum Community of Global Growth
Companies. For 20 years, the company has been dedicated to the discovery,
development and commercialization of innovative products in four core
therapeutic areas: central nervous system, pain, oncology and addiction. A
member of the Fortune 1000, Cephalon currently employs nearly 3,000 people
in the United States and Europe. U.S. sites include the company's
headquarters in Frazer, Pennsylvania, and offices, laboratories or
manufacturing facilities in West Chester, Pennsylvania, Salt Lake City,
Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters
are located in Maisons-Alfort, France.
The company's proprietary products in the United States include:
PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA, TRISENOX(R) (arsenic
trioxide) injection, AMRIX(R) (cyclobenzaprine hydrochloride
extended-release capsules), VIVITROL(R) (naltrexone for extended-release
injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM)
(armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl
citrate) [C-II]. The company also markets numerous products
internationally. Full prescribing information on its U.S. products is
available at http://www.cephalon.com or by calling 1-800-896-5855.
In addition to historical facts or statements of current condition,
this press release may contain forward-looking statements. Forward-looking
statements provide Cephalon's current expectations or forecasts of future
events. These may include statements regarding anticipated scientific
progress on its research programs; development of potential pharmaceutical
products, including the timing or approval of any current filings for
regulatory approval of FENTORA; interpretation of clinical results,
particularly with respect to the FENTORA clinical trials; manufacturing
development and capabilities; market prospects for its products; sales and
earnings guidance; and other statements regarding matters that are not
historical facts. You may identify some of these forward-looking statements
by the use of words in the statements such as "anticipate," "estimate,"
"expect," "project," "intend," "plan," "believe" or other words and terms
of similar meaning. Cephalon's performance and financial results could
differ materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political conditions
affecting the biotechnology and pharmaceutical industries as well as more
specific risks and uncertainties facing Cephalon such as those set forth in
its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and
Exchange Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect. Therefore, you
should not rely on any such factors or forward- looking statements.
Furthermore, Cephalon does not intend to update publicly any
forward-looking statement, except as required by law. The Private
Securities Litigation Reform Act of 1995 permits this discussion.
SOURCE Cephalon, Inc.
 back to top
Related links:
http://www.cephalon.com
http://www.prnewswire.com/comp/134563.html /
CONTACT:
Media, Stacey Beckhardt, +1-610-738-6198,
sbeckhar@cephalon.com, or Candace Steele, +1-610-727-6231,
csteele@cephalon.com, or Investors, Robert (Chip) Merritt,
+1-610-738-6376, cmerritt@cephalon.com, all of Cephalon, Inc.
|
